Landscape Analysis of Generic Availability for Oncologic Drugs.
ANDA
Generic competition
Machine learning
Oncologic drugs
Journal
Therapeutic innovation & regulatory science
ISSN: 2168-4804
Titre abrégé: Ther Innov Regul Sci
Pays: Switzerland
ID NLM: 101597411
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
13
03
2023
accepted:
24
07
2023
medline:
23
10
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
Improving generic drug development in oncology is a key long-term goal in providing safe, effective, and affordable care to patients with a diagnosis of cancer in the United States. There are multiple drug and non-drug related variables that may influence generic drug development. To illustrate pertinent associations relevant to generic drug competition in oncology, our study assessed variables that have potentially led to difference in generic competition as compared to drug products in other therapeutic areas, i.e., cardiovascular disease in this case. Using a combination of FDA and publicly available data, we categorized individual drug approvals from 1950 to 2021 with either an oncology or cardiovascular indication. Descriptive statistics highlighted the timeline of approval as stratified by indications. Machine learning methodology was used to assess variables associated with abbreviated new drug application (ANDA) availabilities (i.e., generic drug availabilities). Kaplan-Meier analysis with log-rank test compared the difference in the time to approval of first ANDA among products that were off-patent at the time of analysis. A multivariable Cox proportional hazards model with forward selection was used to identify variables (e.g., regulatory recommendation issued, dosage form) that were associated with ANDA availability among products that were off-patent. 434 separate reference listed drugs (RLDs) with varying strengths were identified, 212 (49%) for oncology and 222 (51%) for cardiovascular indications. Compared with cardiovascular products, a greater proportion of RLDs with an oncology indication were approved after 2000 (61% vs. 34%). Also, a smaller proportion of oncologic products had generics (49% vs. 80%). Machine learning methodology revealed RLD age, patent status, product complexity, sales/prescriptions, and regulatory recommendations as variables that were associated with generic availability. Among products off-patent at the time of analysis, the median time from RLD approval to the first ANDA approval was longer for oncologic products compared to cardiovascular products (15.4 years (95% CI 13.8, 17.9) versus 12.3 years (95% CI 10.7, 13.5), p = 0.008). Cox regression analyses identified the variables of product dosage form and regulatory recommendation of requiring patient enrollment for bioequivalence (BE) establishment as being associated with reduced likelihood of ANDA approval for oncologic drugs. Oncology indications were found to have a longer time from RLD approval to first ANDA approval compared with cardiovascular drugs. Our work has identified variables that may influence time to ANDA availability, with the requirement of patient enrollment for BE assessment as one important opportunity for future stakeholder engagement and regulatory considerations.
Sections du résumé
BACKGROUND
Improving generic drug development in oncology is a key long-term goal in providing safe, effective, and affordable care to patients with a diagnosis of cancer in the United States. There are multiple drug and non-drug related variables that may influence generic drug development. To illustrate pertinent associations relevant to generic drug competition in oncology, our study assessed variables that have potentially led to difference in generic competition as compared to drug products in other therapeutic areas, i.e., cardiovascular disease in this case.
METHODS
Using a combination of FDA and publicly available data, we categorized individual drug approvals from 1950 to 2021 with either an oncology or cardiovascular indication. Descriptive statistics highlighted the timeline of approval as stratified by indications. Machine learning methodology was used to assess variables associated with abbreviated new drug application (ANDA) availabilities (i.e., generic drug availabilities). Kaplan-Meier analysis with log-rank test compared the difference in the time to approval of first ANDA among products that were off-patent at the time of analysis. A multivariable Cox proportional hazards model with forward selection was used to identify variables (e.g., regulatory recommendation issued, dosage form) that were associated with ANDA availability among products that were off-patent.
RESULTS
434 separate reference listed drugs (RLDs) with varying strengths were identified, 212 (49%) for oncology and 222 (51%) for cardiovascular indications. Compared with cardiovascular products, a greater proportion of RLDs with an oncology indication were approved after 2000 (61% vs. 34%). Also, a smaller proportion of oncologic products had generics (49% vs. 80%). Machine learning methodology revealed RLD age, patent status, product complexity, sales/prescriptions, and regulatory recommendations as variables that were associated with generic availability. Among products off-patent at the time of analysis, the median time from RLD approval to the first ANDA approval was longer for oncologic products compared to cardiovascular products (15.4 years (95% CI 13.8, 17.9) versus 12.3 years (95% CI 10.7, 13.5), p = 0.008). Cox regression analyses identified the variables of product dosage form and regulatory recommendation of requiring patient enrollment for bioequivalence (BE) establishment as being associated with reduced likelihood of ANDA approval for oncologic drugs.
CONCLUSION
Oncology indications were found to have a longer time from RLD approval to first ANDA approval compared with cardiovascular drugs. Our work has identified variables that may influence time to ANDA availability, with the requirement of patient enrollment for BE assessment as one important opportunity for future stakeholder engagement and regulatory considerations.
Identifiants
pubmed: 37561261
doi: 10.1007/s43441-023-00562-w
pii: 10.1007/s43441-023-00562-w
doi:
Substances chimiques
Drugs, Generic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1279-1286Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983–2018. JAMA. 2020;323(2):164.
doi: 10.1001/jama.2019.20288
pubmed: 31935033
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. A Cancer J Clin. 2020;70(1):7–30.
doi: 10.3322/caac.21590
Park J, Look KA. Health care expenditure burden of cancer care in the United States. J Health Care Organ Provis Financing. 2019;56:004695801988069.
Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the united states: origins and prospects for reform. JAMA. 2016;316(8):858–71.
doi: 10.1001/jama.2016.11237
pubmed: 27552619
Gupta R, et al. Generic drug approvals since the 1984 Hatch-Waxman act. JAMA Intern Med. 2016;176(9):1391.
doi: 10.1001/jamainternmed.2016.3411
pubmed: 27428055
Lee C-Y, et al. Forces influencing generic drug development in the United States: a narrative review. J Pharm Policy Practice. 2016. https://doi.org/10.1186/s40545-016-0079-1 .
doi: 10.1186/s40545-016-0079-1
Abbreviated New Drug Application (ANDA). 2021. Available from: https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda .
Dusetzina SB, et al. Medicare part D plans rarely cover brand-name drugs when generics are available. Health Aff (Millwood). 2020;39(8):1326–33.
doi: 10.1377/hlthaff.2019.01694
pubmed: 32744944
Robinson JC, Jarrion Q. Competition from biosimilars drives price reductions for biologics in the French single-payer health system. Health Aff (Millwood). 2021;40(8):1190–7.
doi: 10.1377/hlthaff.2021.00070
pubmed: 34339240
Dusetzina SB, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic Myeloid Leukemia. J Clin Oncol. 2014;32(4):306–11.
doi: 10.1200/JCO.2013.52.9123
pubmed: 24366936
FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 2020. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm .
FDA. Product-Specific Guidances for Generic Drug Development. 2021. Available from: https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm .
Database, I.: Available from: https://www.iqvia.com/ (2021).
Letter, G.D.U.F.A.G.I.C.; Available from: https://www.fda.gov/media/101052/download .
R Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, V., Austria. Available from: https://cran.r-project.org/web/packages/partykit/index.html (2022).
Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006;15(3):651–74.
doi: 10.1198/106186006X133933
FDA Drug Competition Action Plan. 2022. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/fda-drug-competition-action-plan .
Desai S, McWilliams JM. Consequences of the 340B drug pricing program. N Engl J Med. 2018;378(6):539–48.
doi: 10.1056/NEJMsa1706475
pubmed: 29365282
pmcid: 6073067
Miller KL, et al. Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies. Expert Opin Orphan Drugs. 2022;9(11–12):265–72.
pubmed: 35548705
pmcid: 9087212
M9 Biopharmaceutics Classification System Based Biowaivers. 2021. Available from: https://www.fda.gov/media/148472/download .
Implementation of the Biologics Price Competition and Innovation Act of 2009. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/implementation-biologics-price-competition-and-innovation-act-2009 .